News tagged with lenalidomide

Related topics: patients · multiple myeloma

Sorry, no news articles match your request. Your search criteria may be too narrow.

Lenalidomide

Lenalidomide ( /lɛnəˈlɪdɵmaɪd/), initially known as CC-5013 and marketed as Revlimid by Celgene, is a derivative of thalidomide introduced in 2004.

It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide and bortezomib are considered therapeutic breakthroughs in the treatment of myeloma, which generally carries a poor prognosis.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed